{
    "clinical_study": {
        "@rank": "19888", 
        "arm_group": [
            {
                "arm_group_label": "PD 0360324", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in\n      subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care\n      therapies."
        }, 
        "brief_title": "A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Sarcoidosis", 
        "condition_browse": {
            "mesh_term": [
                "Sarcoidosis", 
                "Sarcoidosis, Pulmonary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of biopsy-proved chronic pulmonary sarcoidosis either Stage 2 or Stage 3\n             for at least 1 year;\n\n          -  Forced Vital Capacity (FVC) lung assessment of >40% and < or = to 80% predicted\n             normal values at screening;\n\n          -  age 21-75 years of age;\n\n          -  treatment with a stable (longer than 4 weeks) regimen of corticosteroids (between 10\n             and 30 mg of prednisone) for at least 3 months prior to Screening; (other\n             anti-inflammatory drugs may be permitted as defined by the study protocol)\n\n        Exclusion Criteria:\n\n          -  History of any other pulmonary (lung) disease than sarcoidosis (ex, asthma requiring\n             maintenance treatment, chronic obstructive pulmonary disease (COPD));\n\n          -  Pulmonary hypertension, significant lung fibrosis, any chronic infection (eg, TB,\n             HIV);\n\n          -  treatment with other biologic anti-inflammatory/immuno-modulatory drugs;\n\n          -  active smokers;\n\n          -  class 3 or 4 congestive heart failure;\n\n          -  cancer, or history of cancer within past 5 years;\n\n          -  history of ischemic heart disease, heart attack, stroke, any heart muscle disease;\n\n          -  liver disease;\n\n          -  history of alcohol or drug abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732211", 
            "org_study_id": "A6261009"
        }, 
        "intervention": [
            {
                "arm_group_label": "PD 0360324", 
                "description": "100 mg Q2W or 150 mg Q2W  via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;", 
                "intervention_name": "PD 0360324", 
                "intervention_type": "Biological", 
                "other_name": "Investigational Study Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "normal saline Q2W via intravenous infusion for 12 weeks", 
                "intervention_name": "Normal Saline for injection", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Phase 2", 
            "Randomized", 
            "Double Blind", 
            "Placebo Controlled", 
            "Parallel", 
            "20 Week Safety", 
            "Tolerability", 
            "and Efficacy Study"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6261009&StudyName=A%20Phase%202%2C%20Safety%2C%20Tolerability%2C%20and%20Efficacy%20Study%20of%20PD%200360324%20in%20Chronic%20Pulmonary%20Sarcoidosis"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80206"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, 20 Week, Safety, Tolerability, and Efficacy Study of PD 0360324 in Adult Subjects With Chronic Pulmonary Sarcoidosis", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary efficacy endpoint", 
            "measure": "Change from baseline in % predicted Forced Vital Capacity (FVC) compared to placebo at Week 16.", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732211"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary Efficacy Endpoint", 
                "measure": "Change in chest X ray global assessment score (5 point Likert Scale)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 20 weeks"
            }, 
            {
                "description": "Secondary Efficacy Endpoint", 
                "measure": "Change from baseline in FVC (absolute and % predicted) compared to placebo at other time points post baseline except Week 16.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 20 weeks (except Week 16)"
            }, 
            {
                "description": "Secondary Efficacy Endpoint", 
                "measure": "Estimated treatment effect over placebo in FVC averaged over 16 weeks.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 16"
            }, 
            {
                "description": "Secondary Efficacy Endpoint", 
                "measure": "Change from baseline in other spirometric parameters at all timepoints post baseline: Forced Expiratory Volume in 1 Second (FEV1), % predicted FEV1, ratio of FEV1/FVC.", 
                "safety_issue": "No", 
                "time_frame": "all timepoints post baseline"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}